Efficacy and safety of creatine phosphate sodium in the treatment of viral myocarditis: A systematic review and meta-analysis
Wang L, Chen SF, Huang XW, Wu ZY, Zhang QM
PloS one · 1 cita
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2025-01-24 · PLoS One · vol. 20 · número 1 · pág. e0317498
- Editorial
- Public Library of Science
- Citado
- 2 citas · más que el 56% de estudios similares · 0.6× el promedio de su campo
- Referencias
- 50 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Viral Infections and Immunology Research · Cardiomyopathy and Myosin Studies · Cardiovascular Effects of Exercise
- Palabras clave
- Phosphocreatine, Cochrane Library, Medicine, Meta-analysis, Internal medicine, Creatine, Creatine kinase, Randomized controlled trial, Gastroenterology, Publication bias
- MeSH
- humans, virus diseases, myocarditis, phosphocreatine, treatment outcome, randomized controlled trials as topic
5 autores
- Li Wang
- Sufang Chen🇨🇳The 180th Hospital of PLA; Chinese People's Liberation Army
- Xiwei Huang
- Zhiyang Wu
- Qingmei Zhang🇨🇳 · autor de correspondenciaAffiliated Hangzhou First People's Hospital, Westlake University, School of Medicine
Resumen
El texto original del estudio, en el idioma en que se publicó.
Purpose
To systematically evaluate the efficacy and safety of creatine phosphate sodium in the treatment of viral myocarditis, and to provide guidance for its clinical treatment.
Methods
We conducted a search of The Cochrane Library, PubMed, EMbase, and Web of Science databases to retrieve randomized controlled trials (RCTs) on the use of creatine phosphate sodium (CPS) in the treatment of viral myocarditis. The search was conducted up to April 2024. After screening the literature, extracting data, and evaluating the risk of bias in the included studies, we performed a meta-analysis using RevMan 5.4 and Stata17.0 statistical software.
Results
A total of 104 articles were retrieved, and 9 articles with a combined total of 1,116 patients were ultimately included in the meta-analysis. The results of the meta-analysis indicated that the overall efficacy rate in the phosphocreatine sodium treatment group was higher than that in the control group [RR = 1.22, 95%CI (1.15, 1.28), P<0.00001]. Furthermore, post-treatment levels of cardiac troponin I [MD = 0.1, 95%CI (0.07, 0.13), P<0.00001] and creatine kinase isoenzyme [MD = 9.43, 95%CI (7.04,11 .82), P<0 .00001] in the phosphocreatine treatment group were lower compared to those in the control group; both differences between groups were statistically significant. Additionally, there was no significant difference observed in adverse reaction incidence between the phosphocreatine sodium treatment group and conventional treatment group [RR = 1 .07, 95% CI (0 .68, 1 .67), P = O .77].
Conclusion
Creatine phosphate sodium treatment can significantly improve the therapeutic effect of patients with viral myocarditis, and can reduce the levels of cTnI and CK-MB. Compared with conventional treatment, it has good safety.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.